Your browser doesn't support javascript.
loading
Identification of a serum-based microRNA signature that detects recurrent oral squamous cell carcinoma before it is clinically evident.
Towle, Rebecca; Dickman, Christopher T D; MacLellan, Sara A; Chen, Jiahua; Prisman, Eitan; Guillaud, Martial; Garnis, Cathie.
Afiliação
  • Towle R; Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Dickman CTD; Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • MacLellan SA; Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Chen J; Department of Statistics, University of British Columbia, Vancouver, BC, Canada.
  • Prisman E; Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
  • Guillaud M; Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Garnis C; Department of Integrative Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada. cgarnis@bccrc.ca.
Br J Cancer ; 129(11): 1810-1817, 2023 11.
Article em En | MEDLINE | ID: mdl-37798371
BACKGROUND: Survival rates for oral squamous cell carcinoma (OSCC) have remained poor for decades, a fact largely attributable to late-stage diagnoses and high recurrence rates. We report analysis of serum miRNA expression in samples from patients with high-risk oral lesions (HRL, including OSCC/carcinoma in situ lesions) and healthy non-cancer controls, with the aim of non-invasively detecting primary or recurrent disease before it is clinically evident. METHODS: Discovery, test, and validation sets were defined from a total of 468 serum samples (305 HRL and 163 control samples). Samples were analysed using multiple qRT-PCR platforms. RESULTS: A two-miRNA classifier comprised of miR-125b-5p and miR-342-3p was defined following discovery and test analyses. Analysis in an independent validation cohort reported sensitivity and specificity of ~74% for this classifier. Significantly, when this classifier was applied to serial serum samples taken from patients both before treatment and during post-treatment surveillance, it identified recurrence an average of 15 months prior to clinical presentation. CONCLUSIONS: These results indicate this serum miRNA classifier is effective as a simple, non-invasive monitoring tool for earlier detection of recurrent disease when lesions are typically smaller and amenable to a wider array of treatment options to improve survival.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / MicroRNAs / Neoplasias de Cabeça e Pescoço Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / MicroRNAs / Neoplasias de Cabeça e Pescoço Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article